Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
about
H-gemcitabine: a new gemcitabine prodrug for treating cancerCurrent and emerging therapies for the treatment of pancreatic cancer.In vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.Folate-chitosan-gemcitabine core-shell nanoparticles targeted to pancreatic cancerStearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.Harnessing gemcitabine metabolism: a step towards personalized medicine for pancreatic cancer.Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models.Improving nucleoside analogs via lipid conjugation: Is fatter any better?Lipophilic prodrugs and formulations of conventional (deoxy)nucleoside and fluoropyrimidine analogs in cancer.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Elacytarabine: lipid vector technology under investigation in acute myeloid leukemia.Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement.Novel developments in the use of antimetabolites.Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.A first-in-human phase I and pharmacokinetic study of CP-4126 (CO-101), a nucleoside analogue, in patients with advanced solid tumours.Synthesis and cytostatic evaluation of 4-N-alkanoyl and 4-N-alkyl gemcitabine analogues.Metabolism, mechanism of action and sensitivity profile of fluorocyclopentenylcytosine (RX-3117; TV-1360).Metabolism and accumulation of the lipophilic deoxynucleoside analogs elacytarabine and CP-4126Development and characterization of a long-acting nanoformulated abacavir prodrugOral 4-(N)-stearoyl gemcitabine nanoparticles inhibit tumor growth in mouse models.Pancreatic Cancer Chemoresistance to Gemcitabine.Fluorinated nucleosides as an important class of anticancer and antiviral agents.Vitamin E Phosphate Nucleoside Prodrugs: A Platform for Intracellular Delivery of Monophosphorylated Nucleosides.The 4-N-acyl and 4-N-alkyl gemcitabine analogues with silicon-fluoride-acceptor: Application to 18F-Radiolabeling.
P2860
Q33572635-6C6F690C-149B-47DA-AC45-189CB7E270E0Q34129346-FAB0281C-1AC7-4339-B48A-3B4B28C885CCQ34819537-2923D432-F22D-48AE-AEC5-D1203709D8EAQ35047386-590CAC51-FAD3-43FD-B782-376FD5FDE834Q35610203-400ABB7B-D38C-4A37-B9BA-3ABBC45E0FE0Q36348451-AFBECA1A-EF1B-41EF-8D2F-5907D7D64993Q36557707-43D456D8-5AAE-4183-B5B7-189388220D2BQ36706248-CE2FD7DC-36F4-49D6-8C8D-A21B82C66557Q37963493-E3C9B2DE-080D-45AB-A378-9FC209112E26Q37994505-FF512017-D642-4329-8ECD-A13738DD5A5FQ38078423-0C253C92-2B51-48E3-AC6A-E34BC6433648Q38082728-27C77BE5-4DE4-49A9-9487-320D41DEA45AQ38221152-EEBFC922-3DC9-42B7-9C5B-710AC16BA314Q38673319-6C16FA49-0803-4496-B14A-C3B954591C8CQ38972651-6489F6CE-8AEA-40DF-8A10-95C2942DB8F0Q39042999-E82EFCC7-32B6-4BED-BDD8-73504792471AQ39094261-64CE96AC-8F6D-4FE4-A019-6BD95C2C2EEEQ39457478-1C0D99C5-2D52-4006-9358-E60DAA9C7BC0Q41280373-1664CF7D-0728-46B7-80ED-0D07904EB009Q45729918-F4C026FC-A27A-45E3-B912-FD6A54B182E4Q47135556-675D251E-2897-4910-AEB6-AA7C03A4DF5EQ47637142-4E413406-708A-454F-BB79-55C89E87E15AQ50132096-444EB05A-CA07-436F-BE4E-7D7C4CFE1ECFQ52931150-9C99AFA0-915B-4F51-9457-73C2D9B691C2
P2860
Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Antiproliferative activity, me ...... itro and in vivo tumor models.
@ast
Antiproliferative activity, me ...... itro and in vivo tumor models.
@en
Antiproliferative activity, me ...... itro and in vivo tumor models.
@nl
type
label
Antiproliferative activity, me ...... itro and in vivo tumor models.
@ast
Antiproliferative activity, me ...... itro and in vivo tumor models.
@en
Antiproliferative activity, me ...... itro and in vivo tumor models.
@nl
prefLabel
Antiproliferative activity, me ...... itro and in vivo tumor models.
@ast
Antiproliferative activity, me ...... itro and in vivo tumor models.
@en
Antiproliferative activity, me ...... itro and in vivo tumor models.
@nl
P2093
P2860
P1476
Antiproliferative activity, me ...... vitro and in vivo tumor models
@en
P2093
Andries M Bergman
Auke D Adema
Finn Myhren
Godefridus J Peters
Iduna Fichtner
Jan Balzarini
Marit L Sandvold
Oystein Fodstad
Paul Noordhuis
Skjalg Bruheim
P2860
P2888
P304
P356
10.1007/S10637-009-9377-7
P577
2010-01-12T00:00:00Z
P5875
P6179
1002295981